Pidotimod: the state of art

Area of Science:

• Immunology
• Pharmacology

Background:

• Recurrent respiratory tract infections pose a significant health burden, particularly in vulnerable populations like children and the elderly.
• Existing treatments like antibiotics and vaccines have limitations, increasing the need for effective immunostimulants.

Purpose of the Study:

• To review the efficacy and safety of Pidotimod, a synthetic dipeptide, in managing respiratory tract infections.
• To evaluate Pidotimod's immunomodulatory effects on both innate and adaptive immunity.

Main Methods:

• Systematic review of studies focusing on Pidotimod's use in patients with recurrent respiratory tract infections, including those with asthma or COPD.
• Analysis of clinical and laboratory parameters, including immune cell function, salivary IgA levels, and respiratory function tests.

Main Results:

• Pidotimod demonstrated significant immunomodulatory activity, enhancing immune cell function and improving clinical outcomes.
• Key benefits included a reduction in infectious episodes, decreased symptom severity, and less reliance on antibiotics.
• The drug showed a good safety profile with a low incidence of side effects and no serious adverse events.

Conclusions:

• Pidotimod is an effective immunostimulant for preventing and attenuating respiratory tract infections, especially in children and the elderly.
• Its ability to modulate both innate and adaptive immunity, coupled with a favorable safety profile, makes it a valuable therapeutic option.
• Pidotimod also presents a safer alternative for patients undergoing vaccination compared to other immunomodulators.